Fluvoxamine maleate(DU23000 maleate)

Molecular Weight (MW)	434.41
Formula	C14H18F3N2O2.C4H4O4
CAS No.	61718-82-9 (maleate);
Storage	-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)	DMSO: 87 mg/mL (200.3 mM)
Water: <1 mg/mL
Ethanol: 87 mg/mL (200.3 mM)
Solubility (In vivo)	Chemical Name: 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine maleate InChi Key: LFMYNZPAVPMEGP-PIDGMYBPSA-N InChi Code: InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1- SMILES Code: FC(C1=CC=C(/C(CCCCOC)=N/OCCN)C=C1)(F)F.O=C(O)/C=C\C(O)=O
Synonyms	DU-23000 maleate; Fluvoxamine maleate, DU 23000; MK264; MK 264; DU23000; Faverin, Fevarin, Floxyfral, Luvox; MK-264;

Molecular Weight (MW)

434.41

Formula

C14H18F3N2O2.C4H4O4

CAS No.

61718-82-9 (maleate);

Storage

-20℃ for 3 years in powder form

-80℃ for 2 years in solvent

Solubility (In vitro)

DMSO: 87 mg/mL (200.3 mM)

Water: <1 mg/mL

Ethanol: 87 mg/mL (200.3 mM)

Solubility (In vivo)

Chemical Name: 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine maleate
InChi Key: LFMYNZPAVPMEGP-PIDGMYBPSA-N
InChi Code: InChI=1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-
SMILES Code: FC(C1=CC=C(/C(CCCCOC)=N/OCCN)C=C1)(F)F.O=C(O)/C=C\C(O)=O

Synonyms

DU-23000 maleate; Fluvoxamine maleate, DU 23000; MK264; MK 264; DU23000; Faverin, Fevarin, Floxyfral, Luvox; MK-264;

In Vitro	In vitro activity: Fluvoxamine increases [5-HT]ex levels in rat the prefrontal cortex and thalamus, and also increases [DA]ex levels in the striatum. Fluvoxamine maleate ameliorates tactile allodynia via spinal 5-HT2A/2C receptors, by acting on the receptors or 5-HT neurons.
In Vivo	Fluvoxamine maleate also exhibits the antinociception in a dose-dependent manner in the paw pressure test in non-ligated mice. Fluvoxamine maleate also induces antinociceptive effect in the acute paw pressure test, and this effect is antagonized by the 5-HT3 receptor antagonist granisetron. Fluvoxamine (10 and 30 mg/kg, i.p.) enhances synaptic efficacy in the hippocampo-mPFC pathway in a dose-dependent manner in the rat hippocampo-medial prefrontal cortex (mPFC). Fluvoxamine (10 and 30 mg/kg, i.p.) suppresses long-term potentiation (LTP) in the hippocampal CA1 field of anesthetized rats. Fluvoxamine (30 mg/kg, i.p.)-induced suppression of LTP is completely reversed by the 5-HT(1A) receptor antagonist NAN-190 (0.5 mg/kg, i.p), but not by the 5-HT(4) receptor antagonist GR 113808 (20 mg/rat, i.c.v.) and the 5-HT(7) receptor antagonist DR 4004 (10 mg/rat, i.c.v.). Fluvoxamine maleate reinforces the response to norepinephrine of isolated rat vas deferens incubated in Krebs-Henseleit solution. Fluvoxamine maleate and Fluoxetine hydrochloride inhibit the contraction induced by potassium ion on the isolated rat uterus preparation with IC50 of 3.99μM and 18.2μM, respectively.
Animal model	Non-ligated mice
Formulation & Dosage	10 and 30 mg/kg, i.p.
References	Psychopharmacology (Berl). 2004 Nov;176(2):195-203; Neuropharmacology. 2006 Sep;51(4):866-72.

In Vitro

In vitro activity: Fluvoxamine increases [5-HT]ex levels in rat the prefrontal cortex and thalamus, and also increases [DA]ex levels in the striatum. Fluvoxamine maleate ameliorates tactile allodynia via spinal 5-HT2A/2C receptors, by acting on the receptors or 5-HT neurons.

In Vivo

Fluvoxamine maleate also exhibits the antinociception in a dose-dependent manner in the paw pressure test in non-ligated mice. Fluvoxamine maleate also induces antinociceptive effect in the acute paw pressure test, and this effect is antagonized by the 5-HT3 receptor antagonist granisetron. Fluvoxamine (10 and 30 mg/kg, i.p.) enhances synaptic efficacy in the hippocampo-mPFC pathway in a dose-dependent manner in the rat hippocampo-medial prefrontal cortex (mPFC). Fluvoxamine (10 and 30 mg/kg, i.p.) suppresses long-term potentiation (LTP) in the hippocampal CA1 field of anesthetized rats. Fluvoxamine (30 mg/kg, i.p.)-induced suppression of LTP is completely reversed by the 5-HT(1A) receptor antagonist NAN-190 (0.5 mg/kg, i.p), but not by the 5-HT(4) receptor antagonist GR 113808 (20 mg/rat, i.c.v.) and the 5-HT(7) receptor antagonist DR 4004 (10 mg/rat, i.c.v.). Fluvoxamine maleate reinforces the response to norepinephrine of isolated rat vas deferens incubated in Krebs-Henseleit solution. Fluvoxamine maleate and Fluoxetine hydrochloride inhibit the contraction induced by potassium ion on the isolated rat uterus preparation with IC50 of 3.99μM and 18.2μM, respectively.

Animal model

Non-ligated mice

Formulation & Dosage

10 and 30 mg/kg, i.p.

References

Psychopharmacology (Berl). 2004 Nov;176(2):195-203; Neuropharmacology. 2006 Sep;51(4):866-72.

CAS NO:	61718-82-9
规格:	≥98%

包装	价格(元)
25mg	询价
50mg	询价
100mg	询价
250mg	询价
500mg	询价
1g	询价
2g	询价